MedTrace Logo

A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF

NCT06335082 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2026-05-22

No results posted yet for this study

Summary

The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF).

Conditions

Interventions

DEVICE

Pulsed Field Ablation

Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Heart Rhythm Clinical and Research Solutions, LLC

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2026-11-30
Completion
2027-01-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06335082 on ClinicalTrials.gov